Nasoxyl (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Nasoxyl, is an imidazoline nasal decongestant presented as a nasal spray for topical nasal use. It relieves nasal blockage associated with the common cold, sinusitis and allergic rhinitis in adults and children when appropriate.

GNH USA supplies Nasoxyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Nasoxyl, containing xylometazoline, acts on the nasal mucosa to reduce congestion in several upper‑respiratory conditions.

- Common cold nasal congestion: rapid reduction of swelling and improved airflow. - Acute sinusitis: alleviation of nasal blockage facilitating sinus drainage. - Allergic rhinitis: relief of congestion and nasal pressure caused by allergen exposure.

Nasal administration of xylometazoline may be associated with a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing or mild headache.

Serious or Rare Side Effects: - Rebound nasal congestion with prolonged use. - Elevated blood pressure or hypertensive crisis. - Severe allergic reactions such as anaphylaxis or nasal ulceration.

When using Nasoxyl, several precautions should be observed to ensure safe and effective treatment.

- Duration of use: limit to no more than three consecutive days to avoid rebound congestion. - Age restrictions: avoid in children under six years unless directed by a healthcare professional. - Cardiovascular conditions: use with caution in patients with hypertension or heart disease. - Concurrent nasal decongestants: do not combine with other topical decongestants to prevent excessive vasoconstriction. - Pregnancy and lactation: safety has not been established; consult a physician before use. - Store at room temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Xylometazoline may interact with certain systemic and topical agents; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Other intranasal decongestants (e.g., phenylephrine, oxymetazoline): risk of additive vasoconstriction and severe hypertension. - Monoamine oxidase inhibitors (MAOIs): potential for hypertensive episodes when combined with sympathomimetic agents. - Systemic sympathomimetics (e.g., pseudoephedrine) in high doses: may amplify cardiovascular effects.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: nasal decongestant may reduce their efficacy, requiring blood pressure monitoring. - Tricyclic antidepressants: possible increase in sympathetic activity. - Alcohol: may enhance dizziness or nasal irritation. - Nasal corticosteroids: generally safe but monitor for local irritation.